Posts by: Rachita Narsaria, MD

A new study reported that smoking might influence the course of progression in IPF patients, although further investigation is needed to better understand this association. Previous research has shown that cigarette smoking ... Read more

August 21, 2017August 21, 2017

Prometic, SRAM to Jointly Advance 3 Fibrosis, Scleroderma Therapies for Booming Chinese Market

Idiopathic Pulmonary Fibrosis, News

Canada’s Prometic Life Sciences and Shenzhen Royal Asset Management (SRAM) will jointly manufacture, develop and commercialize three fibrosis and scleroderma therapies in China, the two companies announced. namely the drugs PBI-4050, PBI-4547 and PBI-4425. A new subsidiary, ... Read more

August 14, 2017August 14, 2017

Potential Therapy, GLPG1690, Seen to Halt Worsening of Lung Fibrosis in Phase 2 Trial

Idiopathic Pulmonary Fibrosis, News

Topline results from a Phase 2a clinical trial show that GLPG1690 successfully halted the worsening of idiopathic pulmonary fibrosis (IPF) in patients, its developer, the Belgian biotechnology firm Galapagos, announced. A double-blind, randomized, placebo-controlled trial, ... Read more